Download PDF
Horm Metab Res 2021; 53(12): 779-786
DOI: 10.1055/a-1661-4420
Endocrine Care

Thresholds of Basal- and Calcium-Stimulated Calcitonin for Diagnosis of Thyroid Malignancy

Authors

  • Mara Băetu 

    1   “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
    2   “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

  • Cristina Alexandra Olariu

    1   “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania

  • Cristina Stancu

    1   “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania

  • Andra Caragheorgheopol

    1   “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
    2   “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

  • Dumitru Ioachim

    1   “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania

  • Gabriel Moldoveanu

    1   “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania

  • Cristina Corneci

    1   “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania

  • Corin Badiu

    1   “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
    2   “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Further Information
Also available at
  Permissions and Reprints
Preview

Abstract

Since medullary thyroid carcinoma is an aggressive cancer, it is important to have an early detection based on stimulated calcitonin (CT), especially when basal-CT is slightly elevated. The objective of this work was to set specific thresholds for basal-CT- and calcium-stimulated calcitonin for prediction of thyroid malignancy in female population. The study included 2 groups: group A-women with elevated basal-CT (>9.82 pg/ml) and group B-women with normal basal-CT (control group). After calcium stimulation test precise protocol, histopathological reports of those that required surgery were correlated with both basal and stimulated calcitonin. The best basal and stimulated calcitonin cut-offs for distinguishing female patients with medullary thyroid carcinoma or C-Cell-hyperplasia from other pathologies or normal cases were: 12.9 pg/ml, respectively 285.25 pg/ml. For basal-CT above 30 pg/ml, malignancy was diagnosed in 9/9 patients (100%): 9 MTC. For stimulated calcitonin above 300 pg/ml, malignancy was diagnosed in 17/21 patients (80.95%): 12 MTC and 5 papillary thyroid carcinomas. The smallest nodule that proved to be medullary thyroid carcinoma had only 0.56/0.34/0.44 cm on ultrasound, with no other sonographic suspicious criteria. In conclusion, we have identified in Romanian female population basal and stimulated calcitonin thresholds to discriminate medullary thyroid carcinoma or C-Cell-hyperplasia from other cases. We recommend thyroid surgery in all women with stimulated calcitonin above 285 pg/ml. Further studies on larger groups are necessary to establish and confirm male and female cut-offs for early diagnosis of medullary thyroid carcinoma, and interestingly, maybe for macro-papillary thyroid carcinomas alike. The calcium administration has minimum side-effects, but continuous cardiac monitoring is required.

Key words

calcitonin - stimulation test - thresholds - cut-off - medullary thyroid carcinoma


Publication History

Received: 16 July 2021

Accepted after revision: 27 September 2021

Article published online:
22 October 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany